<DOC>
	<DOCNO>NCT01251458</DOCNO>
	<brief_summary>This phase I/II study evaluate dose limited toxicity efficacy Torisel</brief_summary>
	<brief_title>Hepatocellular Carcinoma ( HCC ) _Torisel_</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm hepatocellular carcinoma amenable curative resection measurable disease Age &gt; =18 year . Life expectancy great 12 week . ECOG performance status &lt; = 2 Prior systemic therapy HCC allow Adequate haematologic , renal hepatic function Absence cirrhosis Child 's A cirrhosis Fasting total cholesterol &lt; 9.1 mmol/liter fast triglyceride level &lt; 4.5 mmol/liter ) Patients systemic therapy radiotherapy within 3 week prior enter study recover adverse event due agent administer 3 week earlier . Patients receive investigational agent concurrently . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . Uncontrolled intercurrent disease , limit , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>